SB's Factive not approved

Published: 3-Feb-2001


SmithKline Beecham has received a non-approval letter from the FDA for its antibiotic gemifloxacin mesylate (Factive). Although disappointed with the decision, the company says it still intends to pursue the product.

See more

You may also like

Pharmaceutical
OGT begins full IVDR transition for CytoCell FISH probe portfolio

OGT begins full IVDR transition for CytoCell FISH probe portfolio

Read more
OGT has launched two IVDR-certified prenatal FISH probe kits as it begins transitioning its full CytoCell portfolio ahead of the EU’s 2028 Class C deadline

Trending Articles

  1. CellCarta adds Tempus to companion diagnostic commercialisation network CellCarta has partnered with Tempus to expand its CDx Commercialization Lab Network, giving biopharma sponsors a route from companion diagnostic development and regulatory approval to commercial testing in US oncology practice
  2. Fridge-free tetanus-diphtheria vaccine passes first human trial Stablepharma's SPVX02 vaccine remains stable at 30°C for two years, new Phase I data shows, easing cold-chain dependence
  3. FDA escalates action against Dabur India over systemic data-integrity and cGMP failures The US FDA has issued a warning letter to Dabur India following an inspection that identified falsified records, missing laboratory data, inadequate cleaning and process validation and weaknesses in quality-unit oversight, saying the company's response failed to address the systemic nature of the deficiencies
  4. Thermo Fisher Scientific launches new general purpose centrifuges with natural refrigerant cooling New X2 and S2 Series centrifuges combine precise performance with improved sustainability for research, biopharma and clinical laboratories
  5. SCHOTT Pharma expands portfolio for sensitive biologics with cartriQ BioPure The new high‑performance sterile glass cartridge is engineered for stability of complex biologics across their shelf life. It complements EVERIC pure vials and syriQ BioPure syringes, enabling an unbiased container choice across the drug lifecycle. Commercial launch is planned for year‑end at CPHI Milan 2026; samples are already available

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Pharmaceutical
OGT begins full IVDR transition for CytoCell FISH probe portfolio

OGT begins full IVDR transition for CytoCell FISH probe portfolio

OGT has launched two IVDR-certified prenatal FISH probe kits as it begins transitioning its full CytoCell portfolio ahead of the EU’s 2028 Class C deadline
Regulatory
Meet growing chemical containment demands with ControlTech

Meet growing chemical containment demands with ControlTech

Sherwin-Williams’ advanced coating systems provide robust protection for secondary containment areas: keeping assets, people, the environment, and compliance safe
Research & Development
Norstella launches Atlas, an agentic AI platform built on biopharma's most connected data

Norstella launches Atlas, an agentic AI platform built on biopharma's most connected data

New platform combines Norstella's proprietary data assets with purpose-built AI agents to deliverdecision-ready outputs across the drug development lifecycle
Pharmaceutical
CellCarta adds Tempus to companion diagnostic commercialisation network

CellCarta adds Tempus to companion diagnostic commercialisation network

CellCarta has partnered with Tempus to expand its CDx Commercialization Lab Network, giving biopharma sponsors a route from companion diagnostic development and regulatory approval to commercial testing in US oncology practice
Drug Delivery
Fridge-free tetanus-diphtheria vaccine passes first human trial

Fridge-free tetanus-diphtheria vaccine passes first human trial

Stablepharma's SPVX02 vaccine remains stable at 30°C for two years, new Phase I data shows, easing cold-chain dependence
Manufacturing
Edwards cryogenic portfolio now available globally

Edwards cryogenic portfolio now available globally

Bringing cryogenic cooling and vacuum technologies together in one integrated portfolio for customers worldwide
Drug Delivery
SCHOTT Pharma expands portfolio for sensitive biologics with cartriQ BioPure

SCHOTT Pharma expands portfolio for sensitive biologics with cartriQ BioPure

The new high‑performance sterile glass cartridge is engineered for stability of complex biologics across their shelf life. It complements EVERIC pure vials and syriQ BioPure syringes, enabling an unbiased container choice across the drug lifecycle. Commercial launch is planned for year‑end at CPHI Milan 2026; samples are already available
Subscribe now